Black Diamond Therapeutics, Inc.
BDTX
$3.05
$0.113.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.39% | 63.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.25% | 0.91% | |||
| Operating Income | -124.61% | 455.71% | |||
| Income Before Tax | -118.68% | 453.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -118.68% | 453.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -118.68% | 453.72% | |||
| EBIT | -124.61% | 455.71% | |||
| EBITDA | -124.41% | 458.26% | |||
| EPS Basic | -118.63% | 453.36% | |||
| Normalized Basic EPS | -118.77% | 507.30% | |||
| EPS Diluted | -119.39% | 447.03% | |||
| Normalized Diluted EPS | -119.11% | 500.13% | |||
| Average Basic Shares Outstanding | 0.25% | 0.10% | |||
| Average Diluted Shares Outstanding | -1.51% | 1.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||